Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P13584

UPID:
CP4B1_HUMAN

ALTERNATIVE NAMES:
CYPIVB1; Cytochrome P450-HP

ALTERNATIVE UPACC:
P13584; Q1HBI2; Q8TD85; Q8WWF2; Q8WWU9; Q8WWV0

BACKGROUND:
The enzyme Cytochrome P450 4B1, alternatively named CYPIVB1 or Cytochrome P450-HP, is integral to the body's chemical defense mechanism. It operates within an NADPH-dependent electron transport pathway in liver microsomes, engaging in the oxidation of a broad spectrum of substances, from steroids and fatty acids to xenobiotics. This highlights its critical function in the metabolism of both endogenous and exogenous compounds.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Cytochrome P450 4B1 unveils potential pathways for therapeutic advancements. Given its pivotal role in the metabolism of a myriad of substances, insights into its mechanisms could lead to novel approaches in treating metabolic diseases and enhancing drug efficacy and safety.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.